TABLE 1.
Participant demographics and baseline disease characteristics for participants with PD
| UP0030 (phase 1 study—HPs) | UP0078 (phase 1 study—HPs) | UP0077 (phase 1b study—participants with PD) | |||||
|---|---|---|---|---|---|---|---|
| Part 1 | Part 2 | ||||||
| All UCB0599 N = 45 | All Placebo N = 14 | Fasted UCB0599 n = 3 | Fed UCB0599 n = 3 | All UCB0599 N = 22 | All UCB0599 N = 21 | Placebo N = 10 | |
| Median (range) age (y) | 65.0 (55–74) | 64.0 (55–73) | 25.0 (18–53) | 41.0 (35–47) | 38.0 (21–52) | 66.0 (47–80) | 68.5 (46–76) |
| Female, n (%) | 14 (31.1) | 5 (35.7) | 0 | 0 | 2 (9.1) | 8 (38.1) | 2 (20.0) |
| Median (range) BMI (kg/m2) | 26.40 (20.6–31.4) | 25.50 (20.8–30.8) | 22.50 (22.0–23.6) | 25.70 (23.2–30.1) | 25.15 (20.0–28.7) | 27.60 (20.3–32.0) | 23.10 (20.1–30.5) |
| Race, n (%) | |||||||
| Asian | 0 | 0 | 0 | 0 | 2 (9.1) | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 3 (14.3) | 1 (10.0) |
| White | 45 (100) | 14 (100) | 3 (100) | 3 (100) | 20 (90.9) | 18 (85.7) | 9 (90.0) |
| Median (range) MDS‐UPDRS score | NA | NA | NA | NA | NA | 64.0 (17–111) | 63.0 (41–99) |
| Median (range), Hoehn and Yahr stage at screening | NA | NA | NA | NA | NA | 2.0 (2–3) | 2.0 (2–3) |
| Median (range) duration of PD (mo) | NA | NA | NA | NA | NA | 66.0 (13–179) | 101.0 (35–227) |
| Currently on PD medication, n (%) | NA | NA | NA | NA | NA | 19 (90.5) | 10 (100.0) |
Baseline characteristics were generally well balanced across the groups within each study.
Abbreviations: HPs, healthy participants; PD, Parkinson's disease; BMI, body mass index; MDS‐UPDRS, Movement Disorders Society‐Unified Parkinson's Disease Rating Scale; n/N, number of participants; NA, not applicable.